Lifitegrast - Shire

Drug Profile

Lifitegrast - Shire

Alternative Names: Lifitegrast; SAR-1118; SAR-1119; SHP606; SPD606; Xiidra

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sunesis Pharmaceuticals
  • Developer SARcode Bioscience; Shire
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • No development reported Allergic conjunctivitis; Atopic dermatitis; Diabetic macular oedema; Ocular inflammation; Psoriasis

Most Recent Events

  • 01 Aug 2018 Shire announces intention to re-submit MAA to the European Medicines Agency (EMA) for Dry eyes through a centralised procedure in the fourth quarter of 2018
  • 30 Jun 2018 Regulatory submission withdrawn for Dry eyes in United Kingdom, Denmark, Norway, Sweden, Finland, Germany, Netherlands, France, Italy, Portugal, Spain, Greece (Ophthalmic)
  • 18 Apr 2018 Shire expects European approval of lifitegrast for Dry eyes in second half of 2018 (Shire pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top